KROS
Keros Therapeutics, Inc.
There isn't enough reported data to score KROS yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
KROS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
KROS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
KROS PE Valuation
KROS has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
KROS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect KROS's losses to grow, with revenue declining.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
KROS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.34 | -251% |
| Q2 2026 | -$3.22 | -1106% |
| Q1 2026 | -$2.53 | -$2.36 |
| Q4 2025 | $2.30 | +$7.30 |
| Q3 2025 | $1.55 | +$6.76 |
| Q2 2025 | $0.32 | +$5.45 |
| Q1 2025 | -$0.17 | +$4.98 |
| Q4 2024 | -$5.00 | +$0.20 |
KROS has swung to a loss: it lost $2.34 per share over the past year, after a profit the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over KROS on earnings quality, reporting a profit while its opponent remains loss making.
KROS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $40M | +183% |
| Q1 2026 | $367K | -100% |
| Q4 2025 | $380K | -88% |
| Q3 2025 | $14.1M | +3540% |
| Q2 2025 | $18.2M | +49003% |
| Q1 2025 | $211.2M | +254348% |
| Q4 2024 | $3M | +2027% |
| Q3 2024 | $388K | +4750% |
KROS's revenue is recovering but still below its 2025 peak: $40M last quarter, up 183% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 32% | +141 points |
| Q1 2026 | -7051% | -7123 points |
| Q4 2025 | -7703% | -5952 points |
| Q3 2025 | -109% | +15009 points |
| Q2 2025 | -219% | +136103 points |
| Q1 2025 | 72% | +58485 points |
| Q4 2024 | -1751% | +30735 points |
| Q3 2024 | -15118% | +525882 points |
KROS's operating margin was 32% last quarter, up 251 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over KROS on profitability, with a higher operating margin.
KROS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.3M | +6.9% |
| Q2 2026 | -$20.6M | +$9.8M |
| Q1 2026 | -$3.6M | -102% |
| Q4 2025 | -$27.4M | +$18.9M |
| Q3 2025 | $3.1M | +$34M |
| Q2 2025 | -$30.3M | +$9.8M |
| Q1 2025 | $160.6M | +$206.1M |
| Q4 2024 | -$46.3M | -$20.3M |
KROS has burned cash in almost every quarter: −$48M over the past year, against $87M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over KROS on cash generation, producing positive trailing cash flow while its opponent burns cash.
KROS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +541K shares |
| 1 year | -50% | -20.3M shares |
| 3 years | -31% | -9.3M shares |
| 5 years | -13% | -3M shares |
| Available history | +129% | +11.5M shares |
KROS has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
KROS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -4.2x | Net Cash |
| Q3 2025 | -15.4x | Net Cash |
| Q2 2025 | -412.8x | Net Cash |
KROS has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
KROS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 29.8 | Neutral |
KROS's weekly RSI is 43 (neutral) and its Stochastic is 30 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
KROS PE vs Healthcare Sector
| Metric | KROS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KROS has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KROS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.9 | 7.7% below |
| 20 week MA | $10.9 | 7.5% below |
| 50 week MA | $13.0 | 22% below |
| 100 week MA | $13.5 | 25% below |
| 200 week MA | $30.6 | 67% below |
KROS is in a downtrend: it's below all five of its weekly moving averages, and 67% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over KROS on trend strength, trading above more of its moving averages.
KROS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.6 | $78.5 | +264% |
| 2021 | $78.5 | $58.8 | -25% |
| 2022 | $58.8 | $46.7 | -21% |
| 2023 | $46.7 | $39.8 | -15% |
| 2024 | $39.8 | $16.4 | -59% |
| 2025 | $16.4 | $21.0 | +28% |
| 2026 YTD | $21.0 | $10.1 | -52% |
KROS's yearly returns have swung widely, from +264% in 2020 to −59% in 2024. It's down 52% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over KROS on returns for 2026, with the stronger performance.